Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1549 participants.
Also called NCT01167881
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,549 participants
- Registry
-
NCT01167881 -
2009-016244-39
-
- Other papers using this trial's data
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Canada, Colombia, Czechia, Finland, Hong Kong SAR China, India, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Portugal, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01167881. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-08 (actual). Results posted on 2014-08-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01167881- Content hash
11bd835bf1bef42cf7864452ce830cc5b89840f0fa4375b1f685ffa896d2f1c6